MTOR and melanoma: A recent report in a melanoma patient experiencing kidney allograft rejection following PD‐1 blockade suggests that mTOR inhibitors can increase tolerogenic mechanisms against nontumoral tissue at the same time preserving the activity of checkpoint inhibitors.65